Skip to main content
SMFM 2025 Pregnancy Meeting Main banner
Final Program


Program Book
Icon Legend
Presentation Icons
Additional registration fee required
Additional registration fee required
CME Credit Offered
CME Credit Offered
Abstract Award
Abstract Award
Poster Icons
Additional registration fee required
Additional registration fee required
Faculty have requested this content not be shared on social media
Faculty have requested this content not be shared on social media
CME Credit Offered
CME Credit Offered
Abstract Award
Abstract Award
Back

Poster Session 4

(992) Is the Timing of Gestational Diabetes Screening Associated with Adverse Perinatal Outcomes?

Friday, January 31, 2025
4:00 PM – 6:00 PM  
Objective: Though there is a universal recommendation to screen for gestational diabetes (GDM) from 24-28 weeks, the impact of the timing of screening within this 5-week interval has yet to be studied.  The study objective was to determine whether the gestational age of 2-step GDM screening among those diagnosed with GDM is associated with adverse outcomes

Study Design: A retrospective cohort study of singleton, non-anomalous pregnancies at one institution from 2019-2022 and diagnosed with GDM via the 2-step test. The early cohort included patients screened from 24-26.6 and the late cohort included those screened from 27-28.6. The primary outcome was a composite of perinatal morbidity: macrosomia, shoulder dystocia, hypertensive disorders of pregnancy, cesarean delivery for presumed macrosomia, neonatal intensive care unit (NICU) admission, among other adverse neonatal outcomes. Additional secondary maternal and neonatal outcomes were collected. Bivariate analyses, univariate and multivariate regressions were performed

Results:

Of 433 patients included, 213 (49.2%) screened early and 220 (50.8%) screened late. More patients self-identified as Asian in the early group (p=0.0002) and a larger proportion of patients had 1st trimester GDM screening (p=0.001) in the late group (Table 1). In univariate and multivariate analyses, there were no significant differences in the composite outcome between the groups (late vs early screening: aOR 0.82, 95% CI 0.54-1.26, p=0.36). A significantly higher incidence of macrosomia (7 vs 2.7%, p=0.04) and trend toward increased NICU admission (8.9 vs 4.5%, p=0.07) was seen in the early group (Table 2)


Conclusion:

Among patients diagnosed with GDM using the 2-step test, there was no difference in odds of composite perinatal morbidity among patients screened at the earlier or later end of the 24-28 week screening interval, though there were differences in race and prevalence of early glucose screening between the groups. Additional research is needed to further elucidate these findings and understand the implications of the timing of GDM screening on maternal and neonatal outcomes